Header Logo

Connection

DAVID NELSON to Hepacivirus

Back to Details
This is a "connection" page, showing publications DAVID NELSON has written about Hepacivirus.
DAVID NELSON
Connection Strength
0.589
Hepacivirus
  1. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr; 61(4):1127-35.
    View in: PubMed
    Score: 0.396
  2. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 10 12; 377(15):1448-1455.
    View in: PubMed
    Score: 0.119
  3. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J. 2005 Sep 07; 2:80.
    View in: PubMed
    Score: 0.051
  4. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1594-603.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.